Monitoring of Physical Health in Learning Disability Patients on Antipsychotic Treatment in Lanarkshire, Scotland

References

• Ahmed, Z., Frazer, W. and Kerr, M.P. (2000). Reducing antipsychotic medication in people with learning disability. British Journal of Psychiatry, 176,42–46.
   PubMed Web of Science ®Google Scholar
• Aman, M.G. (1984). Drugs and learning in mentally retarded persons. Advances in Human Psychopharmacology pp 121–63.
   Google Scholar
• American Psychiatric Association; American Diabetes Association;American Association of Clinical Endocronologists; North American Association for the Study of Obesity (2004). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27,596–601.
   Google Scholar
• Baumeister, A.A., Sevin, J.A. and King B.H. (1998). Neuroleptics. Psychotropic Medication and Developmental Disabilities: the international consensus Handbook (eds Reiss S. & Aman M.G.), pp. 133–50. Ohio State University, Ohio.
   Google Scholar
• Brylewslci, J. and Duggan, L. (2004). Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews (3): pp CD000377.
   Google Scholar
• Clarke, D.J., Kelly, S., Thim, K. and Corbett, J.A. (1990). Psychotropic drugs and mental retardation: Intellectual Disabilities and the prescription of drugs for behaviour and for epilepsy in 3 residential settings. Journal of Mental Deficiency Research 28, 229–33.
   Google Scholar
• Cohen, S., Glazewksi, R., Khan, S. and Khan, A. (2001). Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. Journal of Clinical Psychiatry, 62, 114–116.
   PubMed Web of Science ®Google Scholar
• Cohn, T., Prud'homme, D., Streiner, D., Kammeh, H. and Rimmington, G. (2004). Characterising coronary heart disease in chronic schizophrenia: High prevalence of metabolic syndrome. Canadian Journal of Psychiatry, 49, 753–760.
   PubMed Web of Science ®Google Scholar
• Cooper, S., Smiley, E., Morrison, J., Williamson, A. and Allan, L. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. British Journal of Psychiatry, 190,27–35.
   PubMed Web of Science ®Google Scholar
• Crossley, R. and Withers, P (2009). Antipsychotic medication and people with intellectual disabilities: Their knowledge and experience. Journal of Applied Research in Intellectual Disabilities, 22, 77–86.
   Google Scholar
• Deb, S. (2001). Epidemiology of psychiatric illness in adults with intellectual disability. In: Health Evidence Bulletin Wales: Intellectual Disability (eds L. Hamilton-Kirkwood, Z. Ahmed, D. Allen, S. Deb, B. Fraser, B. Lindsay, K. McKenzie, L. Penny & Scotland J.), pp. 14 — 17. NHS Wales, Cardiff. (http://hebw.uwcm.ac.uk.)
   Google Scholar
• Deb, S., Clarke, D. and Unwin, G. (2006). Using medication to manage behaviour problems among adults with a learning disability. University of Birmingham. (//www.ld-medication. bham.ac.uk)
   Google Scholar
• Deb, S. and Fraser, W. (1994). The use of psychotropic medication in people with a learning disability: towards rational prescribing. Human Psychopharmacology, 9, 259–272.
   Web of Science ®Google Scholar
• Deb, S. and Unwin, G.L. (2007). Psychotropic medication for behaviour problems in people with intellectual disability: a review of current literature. Current Opinion in Psychiatry, 20,461–466.
   PubMed Web of Science ®Google Scholar
• Duggan, L. and Brylewslci, J. (2009). Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. Cochrane Database of Systematic Reviews (4): 2009. Article Number: CD000030.
   Google Scholar
• Einfield, S.L. (1990). Guidelines for the use of psychotropic medication in individuals with developmental disabilities. Australia and New Zealand Journal of Developmental Disabilities, 16, 71–73.
   Google Scholar
• Emerson, E. (1995). Challenging Behaviour: Analysis and Intervention in People with Learning Difficulties. Cambridge University Press, Cambridge.
   Google Scholar
• Etherington, J., Sheppard, L.C., Ballinger, B.R. and Fenton, G.W. (1995). Psychotropic drugs in a hospital for intellectual disability: The story of 18 years. Mental Handicap Research, 8, 184–193.
   Google Scholar
• Expert Group (2004). 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. British Journal of Psychiatry (suppl), 47, S112–114.
   Google Scholar
• Gualin B.D. Markowitz J.S., Kaley C.F. Nisbet L.A. and Dufresne R.L. (1999). Clozapine associated elevation in serum triglycerides. American Journal of Psychiatry, 158, 1270–1272.
   Google Scholar
• Gualfieri, C.T., Breuning, S.E., Schroeder, S.R. and Quade, D. (1982). Tardive dyskinesia in mental retarded children, adolescents, and young adults: North Carolina and Michigan studies. Psychopharmacology Bulletin, 18, 62–66.
   Google Scholar
• Henderson, D.C., Cagliero, E., Grey, C., Nasralla, H.R.A., Hayden, D.L. and Schoefield, D. (2000). Clozapine, diabetes, weight gain and lipid abnormalities: A 5 year naturalistic study. American Journal of Psychiatry, 57, 975–981.
   Google Scholar
• Hennessy, S., Bilcer, W.B., Knauss, J. S., Margolis, D.J., Kimmel, S.E., Reynolds, R.E, Glasser, D.B., Morrison, M.E. and Strom, B.L. (2002). Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. British Medical Journal, 325, 1070.
   PubMed Web of Science ®Google Scholar
• Holden, B. and Gitlessen, J.P. (2004). Psychotropic medication in adults with mental retardation: prevalence and prescription practices. Research in Developmental Disabilities, 25, 509–521.
   PubMed Web of Science ®Google Scholar
• Jin, H., Myer, J.M. and Jest, D.V. (2004). Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophrenia Research, 71, 195–212.
   PubMed Web of Science ®Google Scholar
• Kane, J.M. and Liberman, J.A. (1992). Adverse effects of psychotropic drugs. New York: Guilford P378–83.
   Google Scholar
• Larsson, B., Svardsudd, K., Wellin, L., Willhelmeson, L., Bjornthorp, B. and Tibbin, G. (1984). Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death; 13 year follow up of participants in study of men born in 1913. British Medical Journal, 288, 1401–1404.
   PubMed Web of Science ®Google Scholar
• Liperoti, R., Gambassi, G., Laplane, K.L., Chiang, C., Pedone, C., Mor, V. and Bernabei, R. (2005). Conventional and atypical antipsychotics and the risk of hospitalisation for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine, 165, 696–701.
   PubMed Web of Science ®Google Scholar
• Mackin, P., Bishop, D., Waticinson, H., Gallagher, P and Ferrier, N.I. (2007). Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. The British Journal of Psychiatry, 191, 23–29.
   PubMed Web of Science ®Google Scholar
• Manchester, D. (1993). Neuroleptics, learning disability, and the community: some history and mystery. British Medical Journal, 307, 184–187.
   PubMed Web of Science ®Google Scholar
• Marder, S.R, Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Kane, J.M., Lieberman, J.A., Schooloer, N.R., Covell, N., Stroup, S., Weissman, E.M., Wirshing, D.A., Hall, C.S., Pogach, L., PiSunyer, X., Bigger, J.T. Jr, Friedman, A., Kleinberg, D., Yevich, S.J., Davis, B. and Shon S. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 161, 1334–1349.
   PubMed Web of Science ®Google Scholar
• Melkersson, K.I., Hunting, A.L. and Brismar, K.E. (2000). Elevated levels of insulin, leptin and blood lipids in Olanzapine treated patients with schizophrenia or related psychosis. Journal of Clinical Psychiatry, 61, 742–749.
   PubMed Web of Science ®Google Scholar
• Meltzer, H.Y. and Fatemi, S.H. (1998). Treatment of schizophrenia. In: Schatzberg C.B., Nemeroff CB, editor, Textbook of psychopharmacology,secondedition. Washington (DC); American Psychiatric Press; pp762–3.
   Google Scholar
• Melville, C.A., Hamilton, S., Hankey, C.R., Miller, S. and Boyle, S. (2007). The Prevalence and determinants of obesity in adults with intellectual disabilities. Obesity Reviews, 8, 223–230.
   PubMed Web of Science ®Google Scholar
• Meyer, J.M. (2001). Effects of atypical antipsychotics on weight and serum lipid levels. Journal of Clinical Psychiatry, 62 (Supp1.27), 27–34.
   PubMedGoogle Scholar
• Molynem, P., Caine, A. and Emerson, E. (1999). Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings. Journal of Applied Research in Intellectual Disabilities, 12, 46–57.
   Web of Science ®Google Scholar
• Montgomery, J. (2006). Ziprasidone - related agranulocytosis following Olanzapine: induced neutropenia. General Hospital Psychiatry, 28, 83–85.
   PubMed Web of Science ®Google Scholar
• Nakagawa, S., Pederson, L., Olsen, M.L., Mortenson, P.B., Sorensen, H.T. and Johnson, S.P. (2006). Antipsychotics and risk of first time hospitalization for myocardial infarction: a population-based case-control study. Journal of Internal Medicine, 260, 451–458.
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence. Bipolar Disorder (2006). The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guidance 38. //www.Nice.org.uk..
   Google Scholar
• Newcomer, J.W. (2005). Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19(Suppl 1), 1–93.
   PubMed Web of Science ®Google Scholar
• Ray, WA., Chung, C.P., Murray, K.T., Hall, K. and Stein, C.M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine, 360, 225–235.
   PubMed Web of Science ®Google Scholar
• Ray, WA., Meredith, S., Thapa, P.B., Meador, K.G., Hall, K. and Murray, K.T. (2001). Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry, 58, 1161–1176.
   PubMed Web of Science ®Google Scholar
• Regal, R.E., Bffli, J.E. and Glazer, H.M. (1987). Phenothiazine - induced cholestatic jaundice. Clinical Pharmacology, 6, 787–794.
   PubMedGoogle Scholar
• Reilly, J.G., Ayis, S.A., Ferrier, I.N., Jones, S.J. and Thomas, S.H.L. (2002). Thioridazine and sudden unexplained death in psychiatric in-patients. British Journal of Psychiatry, 180, 515–522.
   PubMed Web of Science ®Google Scholar
• Royal College of Psychiatrists (2009). Physical health in mental health. Final report of a sco ping group. United Kingdom, Royal College of Psychiatrists.
   Google Scholar
• Sachdev, P. (1992). Drug-induced movement disorders in institutionalized adults with mental retardation: clinical characteristics and risk factors. Australia and New Zealand Journal of Psychiatry, 26,242–248.
   PubMed Web of Science ®Google Scholar
• Schneeweiss, S. and Avron, J. (2009). Antipsychotic agents and sudden cardiac death - how do we manage the risk? New England Journal of Medicine, 360, 294–296.
   PubMed Web of Science ®Google Scholar
• Sernyak, M.J., Douglas, L., Alarcon, R.D., Losonczy, M.F. and Rosenheck, R. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. American Journal of Psychiatry, 159, 561–566.
   PubMed Web of Science ®Google Scholar
• Singh, N.N., Ellis, C.R. and Wechsler, H. (1997). Psychopharmacoepidemiology of mental retardation: 1966-1955. Journal of Child and Adolescent Psychopharmacology, 7, 255–266.
   PubMed Web of Science ®Google Scholar
• Smith, S.M., O'Keane, V. and Murray, R. (2002). Sexual dysfunction patients taking conventional antipsychotic medication. British Journal of Psychiatry, 181, 49–55.
   PubMed Web of Science ®Google Scholar
• Stone, R.K., May, J.E., Alvarezi, WE and Elliman G. (1989). Prevalence and predication of psychotropic drug use in California Developmental Centres. American Journal of Mental Retardation, 93, 627–632.
   PubMedGoogle Scholar
• Straus, S.M., Blemink, G.S., Dieleman, J.P., van der Lei, J., 't Jong, G.W., Kingma, J.H., Sturkenboom, M.C.J.M. and Stricicer, B.H.C.H. (2004). Antipsychotics and the risk of sudden cardiac death. Archives of International Medicine, 164, 1293–1297.
   PubMed Web of Science ®Google Scholar
• Taylor, D., Paton, C. and Kerwin, R. (2007). The Maudsley Prescribing Guidelines 9th Edition. United Kingdom, Informa Healthcare.
   Google Scholar
• Tsiouris, J.A. (2010). Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment of mistreatment. Journal of Intellectual Disability Research, 54, 1–16.
   PubMed Web of Science ®Google Scholar
• Tyrer, P., Oliver-Africano, P., Romeo, R., Knapp, M., Dickens, S., Bouras, N., Ahmed, Z., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., Kramo, K., Bhaumik, S., Harley, D., Regan, A., Thomas, D., Rao, B., Karatela, S., Lenotre, L., Watson, J., Sonia, A., Crawford, M., Eliahoo, J. and North, B. (2009). Neuroleptics in the treatment of aggressive behaviour for people with intellectual disabilities: a randomised control trial (NACHBID) (2009) Health Technology Assessment, 13, No.21.
   Google Scholar
• Wayne, S., Fenton, M.D. and Chavez, M.R. (2006). Medication-Induced Weight Gain and Dyslipidemia in Patients with Schizophrenia. The American Journal of Psychiatry, 163, 1697–1704.
   PubMed Web of Science ®Google Scholar
• Welsh Office (1996). Welsh Health Survey 1995. Cardiff: Welsh Office.
   Google Scholar
• Williams, H., Clarke, R., Bouras, N., Martin, J. and Holt, G. (2000). Use of the atypical antipsychotic olanzapine and risperidone in adults with intellectual disability. Journal of Intellectual Disability Research, 44, 164–169.
   PubMed Web of Science ®Google Scholar